Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
The Reveal PET/CT system merges PET and CT technologies to generate functional and anatomical data in a single scan, which improves the localization of metabolic hot spots for cancer staging.
FDG, the active metabolite of PET scanning, accumulates not only in disease sites, but also in areas of inflammation and infection. The addition of CAD to the Reveal PET/CT system helps decipher inflammatory isotope uptake from metabolic localization of true malignant pathology so infection or inflammation in the pleural lining will not be mistaken for lung cancer.
Radiology Experience, Breast Density and Screening Mammography: What New Research Reveals
October 4th 2024In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.
Comparing Digital Breast Tomosynthesis to Digital Mammography: What a Long-Term Study Reveals
September 17th 2024In a study involving over 272,000 breast cancer screening exams, digital breast tomosynthesis (DBT) had a higher breast cancer detection rate and a lower rate of advanced cancer presentation at the time of diagnosis in comparison to digital mammography.